Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/9748
Title: New formulations of existing antidepressants: advantages in the management of depression.
Authors: Norman, Trevor R;Olver, James S
Affiliation: Department of Psychiatry, University of Melbourne, Austin & Repatriation Medical Centre, Heidelberg, Victoria, Australia. trevorn@unimelb.edu.au
Issue Date: 2004
Citation: Cns Drugs; 18(8): 505-20
Abstract: For nearly 50 years, antidepressant drugs have been the first-line treatment for various forms of depression. Despite their widespread use, these medications have significant shortcomings, in particular problems of patient compliance due to adverse effects. The introduction of new formulations of existing antidepressant medications may provide patients with benefits in terms of convenience of use. As a consequence, improvements in compliance may lead to better antidepressant efficiency.An orally disintegrating formulation of mirtazapine (mirtazapine SolTab), a once-weekly formulation of fluoxetine, an enantiomer-specific formulation of citalopram (escitalopram), an extended-release formulation of venlafaxine (venlafaxine XR), a controlled-release formulation of paroxetine (paroxetine CR) and intravenous formulations of some of the newer antidepressants have all been evaluated in limited clinical trials. In this article, a review of the pharmacokinetics and clinical evaluations of these formulations is presented. While there do not appear to be major clinical advantages for the new formulations in terms of antidepressant efficacy, none of them is less efficacious than their older counterpart. Indeed, some of the new formulations are more acceptable to patients (fluoxetine once-weekly, paroxetine CR), others have pharmacokinetic advantages (venlafaxine XR, paroxetine CR), while others may have a faster onset of effect (mirtazapine SolTab, intravenous formulations). Further evaluation of some formulations is still required (mirtazapine SolTab, fluoxetine once-weekly), while others (venlafaxine XR, escitalopram) are finding widespread acceptance in clinical practice.
Internal ID Number: 15182220
URI: http://ahro.austin.org.au/austinjspui/handle/1/9748
URL: http://www.ncbi.nlm.nih.gov/pubmed/15182220
Type: Journal Article
Subjects: Animals
Antidepressive Agents.chemistry.therapeutic use
Antidepressive Agents, Second-Generation.chemistry.pharmacology.therapeutic use
Antidepressive Agents, Tricyclic.pharmacology.therapeutic use
Chemistry, Pharmaceutical
Cyclohexanols.chemistry.pharmacology.therapeutic use
Delayed-Action Preparations
Depression.drug therapy
Drug Evaluation
Fluoxetine.chemistry.pharmacology.therapeutic use
Humans
Mianserin.analogs & derivatives.chemistry.pharmacology.therapeutic use
Molecular Conformation
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.